Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.36 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 8/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417814 | 1.00 | HRH3 (0.37) | HRH3ITGB3ITGA2BGHSRALDH1A1 | |
| SCHEMBL31509521 | 0.83 | GHSR (0.41) | HRH3ITGB3ITGA2BGHSRITGAV | |
| SCHEMBL2418713 | 0.80 | ITGB3 (0.42) | ITGB3ITGA2BALDH1A1ITGAVITGB5 | |
| SCHEMBL31509536 | 0.80 | ITGB3 (0.42) | ITGB3ITGA2BALDH1A1ITGAVITGB5 | |
| SCHEMBL4402037 | 0.80 | HRH3 (0.38) | HRH3ITGB3ITGA2BGHSRITGAV | |
| SCHEMBL4410585 | 0.80 | HRH3 (0.38) | HRH3ITGB3ITGA2BGHSRITGAV | |
| SCHEMBL12334338 | 0.80 | HRH3 (0.38) | HRH3ITGB3ITGA2BGHSRITGAV | |
| SCHEMBL14156666 | 0.79 | HRH3 (0.36) | HRH3ITGB3ITGA2BGHSR | |
| SCHEMBL4838771 | 0.79 | HRH3 (0.36) | HRH3ITGB3ITGA2BGHSR | |
| SCHEMBL4838753 | 0.79 | HRH3 (0.36) | HRH3ITGB3ITGA2BGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3864012-B1 | SAVOURY AND MOUTHFULNESS TASTE ENHANCERS | LUCTA S A (ES) | 2023-09-13 | — | — | EP | disclosed |
| US-9750738-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2017-09-05 | — | — | US | disclosed |
| US-9273027-B2 | Arylpiperazine opioid receptor antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-01 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011106039-A1 | ARYLPIPERAZONE OPIOID RECEPTOR ANTAGONISTS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| WO-2006113942-A2 | METHOD OF INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-6552029-B1 | For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis | CELLTECH R&D LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295919-A1 | ARYLPIPERAZINE OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRD1 | HRH3 221/4885ITGB3 1071/4885ITGA2B 2557/4885 |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | CTH, CBS, SLC6A3 | HRH3 3124/4885ITGB3 3980/4885ITGA2B 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.